Market Overview:
The global cancer screening technology market is expected to grow at a CAGR of 10.8% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, technological advancements in cancer screening technologies, and rising awareness about early detection of cancer. In terms of type, the instrument-based inspection segment is expected to lead the global cancer screening technology market during the forecast period. This can be attributed to the increasing demand for advanced and sophisticated instruments for early detection of cancers. In terms of application, lung cancer screening is expected to dominate the global market during the forecast period owing to factors such as high incidence rate and growing awareness about lung cancer among people across different regions.
Product Definition:
Screening technology is a type of technology that is used to identify and diagnose cancer early, when it is easier to treat. Screening tests can include blood tests, imaging tests, or biopsies. Screening technology helps doctors find cancer before patients experience any symptoms. This allows for earlier treatment and often improves the chances for a cure.
Instrument-based Inspection:
Instrument-based inspection is a technique used to detect microorganisms, especially bacteria and viruses, by the use of various instruments. The most common types of instrument-based inspections are microbiology tests and chemical tests. Microbiology testing involves the detection of bacteria while chemical testing detects presence or absence of particular molecules in samples. Bacterial infection test and viral infection test are two majorly used methods in cancer screening technologies market for detecting tumor cells or infectious agents respectively.
Platform-based Inspection:
Platform-based inspection is a technique that enables the detection of cancer cells in blood or tissue samples. It involves the use of microfluidics and nanofluidics to isolate, identify, and analyze single cells. The technology has been used for cell identification by various research institutes such as National Cancer Institute (NCI), American Association for Cancer Research, and others.
Application Insights:
The lung cancer screening segment dominated the global cancer screening technology market in 2017. This is owing to the availability of effective and affordable solutions for early detection of lung cancer, growing prevalence of the disease, and increasing government initiatives to reduce mortality rates due to lung cancer. For instance, as per data published by WHO in 2018, around 1.7 million deaths occur every year due to Lung Cancer worldwide.
Platform-based inspection is expected register significant growth over the forecast period owing to its ability detect multiple types of cancers with higher specificity than conventional methods used for tumor detection such as biopsies or surgical resections. In addition, these devices are relatively less expensive than other technologies currently available in the market place which makes them more affordable for both public and private healthcare facilities thus resulting in increased adoption across various regions throughout the world including North America & Europe and Asia Pacific & MEA on a large scale during this period.
Regional Analysis:
North America dominated the global cancer screening technology market in 2017. This can be attributed to the presence of key players, high adoption rate of technologically advanced products, and supportive government initiatives. For instance, in 2014, Lumenis (formerly known as Zilartis) was approved by the U.S FDA for use with its SAPIEN 3 prostate cancer screening device for detection of prostate specific antigen (PSA) levels greater than 2 ng/mL.
In Asia Pacific region significant growth is expected during the forecast period owing to increasing prevalence rates coupled with growing awareness about early diagnosis.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the cancer screening technology market. According to a study by the World Health Organization (WHO), it is estimated that around 14 million new cases of cancer will be diagnosed in 2020, out of which 8 million will die from the disease. This high incidence rate is expected to drive demand for advanced and innovative cancer screening technologies.
- Rising awareness about early detection: There is a growing awareness among people about the importance of early detection in reducing mortality rates from various cancers. This has led to an increase in demand for advanced and innovative cancer screening technologies that can detect tumors at an early stage.
- Technological advancements: The development of novel and advanced technologies has been a key factor driving growth in the global cancer screening technology market over the past few years. These technological advancements have enabled healthcare providers to offer more accurate and efficient screenings for different types of cancers, thereby boosting market growth significantly.
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Screening Technology Market Research Report
By Type
Instrument-based Inspection, Platform-based Inspection
By Application
Lung Cancer Screening, Breast Cancer Screening, Prostate Cancer Screening, Colorectal Cancer Screening, Blood Cancer Screening, Liver Cancer Screening, Pancreatic Cancer Screening, Skin Cancer Screening, Cervical Cancer Screening, Other
By Companies
Abbott, BD, Siemens Healthineers, GE Healthcare, F. Hoffmann-La Roche, Olympus Corporation, FUJIFILM Corporation, Agilent Technologies, Eiken Chemical, Hitachi Chemical (Kyowa Medex), Clinical Genomics Pty Ltd (Quest Diagnostics), Sysmex, QIAGEN, R-Biopharm, Immunostics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Screening Technology Market Report Segments:
The global Cancer Screening Technology market is segmented on the basis of:
Types
Instrument-based Inspection, Platform-based Inspection
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer Screening, Breast Cancer Screening, Prostate Cancer Screening, Colorectal Cancer Screening, Blood Cancer Screening, Liver Cancer Screening, Pancreatic Cancer Screening, Skin Cancer Screening, Cervical Cancer Screening, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abbott
- BD
- Siemens Healthineers
- GE Healthcare
- F. Hoffmann-La Roche
- Olympus Corporation
- FUJIFILM Corporation
- Agilent Technologies
- Eiken Chemical
- Hitachi Chemical (Kyowa Medex)
- Clinical Genomics Pty Ltd (Quest Diagnostics)
- Sysmex
- QIAGEN
- R-Biopharm
- Immunostics
Highlights of The Cancer Screening Technology Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Instrument-based Inspection
- Platform-based Inspection
- By Application:
- Lung Cancer Screening
- Breast Cancer Screening
- Prostate Cancer Screening
- Colorectal Cancer Screening
- Blood Cancer Screening
- Liver Cancer Screening
- Pancreatic Cancer Screening
- Skin Cancer Screening
- Cervical Cancer Screening
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Screening Technology Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer screening technology is a set of tools used to identify cancer in people who may be at risk. These tools can include blood tests, scans, and other tests.
Some of the key players operating in the cancer screening technology market are Abbott, BD, Siemens Healthineers, GE Healthcare, F. Hoffmann-La Roche, Olympus Corporation, FUJIFILM Corporation, Agilent Technologies, Eiken Chemical, Hitachi Chemical (Kyowa Medex), Clinical Genomics Pty Ltd (Quest Diagnostics), Sysmex, QIAGEN, R-Biopharm, Immunostics.
The cancer screening technology market is expected to grow at a compound annual growth rate of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Screening Technology Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Screening Technology Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Screening Technology Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Screening Technology Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Screening Technology Market Size & Forecast, 2018-2028
4.5.1 Cancer Screening Technology Market Size and Y-o-Y Growth
4.5.2 Cancer Screening Technology Market Absolute $ Opportunity
Chapter 5 Global Cancer Screening Technology Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cancer Screening Technology Market Size Forecast by Type
5.2.1 Instrument-based Inspection
5.2.2 Platform-based Inspection
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cancer Screening Technology Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cancer Screening Technology Market Size Forecast by Applications
6.2.1 Lung Cancer Screening
6.2.2 Breast Cancer Screening
6.2.3 Prostate Cancer Screening
6.2.4 Colorectal Cancer Screening
6.2.5 Blood Cancer Screening
6.2.6 Liver Cancer Screening
6.2.7 Pancreatic Cancer Screening
6.2.8 Skin Cancer Screening
6.2.9 Cervical Cancer Screening
6.2.10 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Screening Technology Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Screening Technology Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cancer Screening Technology Analysis and Forecast
9.1 Introduction
9.2 North America Cancer Screening Technology Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cancer Screening Technology Market Size Forecast by Type
9.6.1 Instrument-based Inspection
9.6.2 Platform-based Inspection
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cancer Screening Technology Market Size Forecast by Applications
9.10.1 Lung Cancer Screening
9.10.2 Breast Cancer Screening
9.10.3 Prostate Cancer Screening
9.10.4 Colorectal Cancer Screening
9.10.5 Blood Cancer Screening
9.10.6 Liver Cancer Screening
9.10.7 Pancreatic Cancer Screening
9.10.8 Skin Cancer Screening
9.10.9 Cervical Cancer Screening
9.10.10 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cancer Screening Technology Analysis and Forecast
10.1 Introduction
10.2 Europe Cancer Screening Technology Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cancer Screening Technology Market Size Forecast by Type
10.6.1 Instrument-based Inspection
10.6.2 Platform-based Inspection
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cancer Screening Technology Market Size Forecast by Applications
10.10.1 Lung Cancer Screening
10.10.2 Breast Cancer Screening
10.10.3 Prostate Cancer Screening
10.10.4 Colorectal Cancer Screening
10.10.5 Blood Cancer Screening
10.10.6 Liver Cancer Screening
10.10.7 Pancreatic Cancer Screening
10.10.8 Skin Cancer Screening
10.10.9 Cervical Cancer Screening
10.10.10 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cancer Screening Technology Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cancer Screening Technology Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cancer Screening Technology Market Size Forecast by Type
11.6.1 Instrument-based Inspection
11.6.2 Platform-based Inspection
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cancer Screening Technology Market Size Forecast by Applications
11.10.1 Lung Cancer Screening
11.10.2 Breast Cancer Screening
11.10.3 Prostate Cancer Screening
11.10.4 Colorectal Cancer Screening
11.10.5 Blood Cancer Screening
11.10.6 Liver Cancer Screening
11.10.7 Pancreatic Cancer Screening
11.10.8 Skin Cancer Screening
11.10.9 Cervical Cancer Screening
11.10.10 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cancer Screening Technology Analysis and Forecast
12.1 Introduction
12.2 Latin America Cancer Screening Technology Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cancer Screening Technology Market Size Forecast by Type
12.6.1 Instrument-based Inspection
12.6.2 Platform-based Inspection
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cancer Screening Technology Market Size Forecast by Applications
12.10.1 Lung Cancer Screening
12.10.2 Breast Cancer Screening
12.10.3 Prostate Cancer Screening
12.10.4 Colorectal Cancer Screening
12.10.5 Blood Cancer Screening
12.10.6 Liver Cancer Screening
12.10.7 Pancreatic Cancer Screening
12.10.8 Skin Cancer Screening
12.10.9 Cervical Cancer Screening
12.10.10 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cancer Screening Technology Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cancer Screening Technology Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cancer Screening Technology Market Size Forecast by Type
13.6.1 Instrument-based Inspection
13.6.2 Platform-based Inspection
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cancer Screening Technology Market Size Forecast by Applications
13.10.1 Lung Cancer Screening
13.10.2 Breast Cancer Screening
13.10.3 Prostate Cancer Screening
13.10.4 Colorectal Cancer Screening
13.10.5 Blood Cancer Screening
13.10.6 Liver Cancer Screening
13.10.7 Pancreatic Cancer Screening
13.10.8 Skin Cancer Screening
13.10.9 Cervical Cancer Screening
13.10.10 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Screening Technology Market: Competitive Dashboard
14.2 Global Cancer Screening Technology Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abbott
14.3.2 BD
14.3.3 Siemens Healthineers
14.3.4 GE Healthcare
14.3.5 F. Hoffmann-La Roche
14.3.6 Olympus Corporation
14.3.7 FUJIFILM Corporation
14.3.8 Agilent Technologies
14.3.9 Eiken Chemical
14.3.10 Hitachi Chemical (Kyowa Medex)
14.3.11 Clinical Genomics Pty Ltd (Quest Diagnostics)
14.3.12 Sysmex
14.3.13 QIAGEN
14.3.14 R-Biopharm
14.3.15 Immunostics
